WYETH ENTERS INTO $32 MILLION CONTRACT WITH NIH FOR ONGOING HIV VACCINE RESEARCH

Wyeth Pharmaceuticals, the pharmaceutical division of Wyeth , has been awarded a five-year, $32 million contract from the Division of AIDS of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of therapeutic HIV vaccines in conjunction with researchers at the University of Pennsylvania, Duke University, and Beth Israel/Deaconess Hospital in New York City.

Finanzen.net (http://finanzen.net/news/news_detail.asp?NewsNr=355081)